CS270537B1 - V144 / 1-2 lymphocyte hybridoma mice - Google Patents

V144 / 1-2 lymphocyte hybridoma mice Download PDF

Info

Publication number
CS270537B1
CS270537B1 CS888155A CS815588A CS270537B1 CS 270537 B1 CS270537 B1 CS 270537B1 CS 888155 A CS888155 A CS 888155A CS 815588 A CS815588 A CS 815588A CS 270537 B1 CS270537 B1 CS 270537B1
Authority
CS
Czechoslovakia
Prior art keywords
type
hybridoma
herpes simplex
glycoprotein
antibody
Prior art date
Application number
CS888155A
Other languages
Czech (cs)
Slovak (sk)
Other versions
CS815588A1 (en
Inventor
Magdalena Ing Csc Bystricka
Gustav Rndr Csc Russ
Pavol Mvdr Csc Ragac
Marta Rndr Miklosova
Original Assignee
Bystricka Magdalena
Russ Gustav
Ragac Pavol
Miklosova Marta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bystricka Magdalena, Russ Gustav, Ragac Pavol, Miklosova Marta filed Critical Bystricka Magdalena
Priority to CS888155A priority Critical patent/CS270537B1/en
Publication of CS815588A1 publication Critical patent/CS815588A1/en
Publication of CS270537B1 publication Critical patent/CS270537B1/en

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Riešenie ge. týká myšieho lymfocytérneho hybridomu, produkujúceho monoklonálnu protilátku proti glykoprateinu gB virusu Herpes simplex typ 1 a typ 2, uloženého v zbierke nybridomov Virologickáho úetgvu SAV v Bratislavě pod označením VU 144/1-2. Monoljlonáliia protilátka produkovaná hybridomom VU 144/1- -2 je vhodná na diagnostické účely v imunofluorescenčnom teste /IF/, v rádioimunoanalytickom teste /RIA/, lmunoenzymatlckej analýze /ELISA/ e v rádioimunoprecipiteénom teste, na stanovenie přítomnosti a množstva virusového antigénu v testovanom materiále. Oe vhodná aj na imunoaflnitnu purifikáciu glykoprotelnu gB z extraktov infikovaných buniek.Solution ge. refers to a murine lymphocytic hybridoma, producing a monoclonal antibody against glycoprotein gB of the Herpes simplex virus type 1 and type 2, stored in the collection of hybridomas of the SAV Virological Unit in Bratislava under the designation VU 144/1-2. The monoclonal antibody produced by hybridoma VU 144/1- -2 is suitable for diagnostic purposes in the immunofluorescence test /IF/, in the radioimmunoanalytical test /RIA/, immunoenzymatic analysis /ELISA/ and in the radioimmunoprecipitation test, to determine the presence and amount of viral antigen in the tested material. Oe also suitable for immunoafflinite purification of glycoprotein gB from extracts of infected cells.

Description

Vynález sa týká nového hybridómu, t.j. hybridného jednobunkového organizmu, zoetrojeného fúziou myšej myelómóvej buňky Sp2/0 a myšej alezinovej lymfoidnej buňky, produkujúcej protilátku vóči glykoproteínu gB virusu Herpes simplex typ 1 a typ 2.The invention relates to a novel hybridoma, i. a hybrid single cell organism, engineered by fusing a mouse Sp2 / 0 myeloma cell and a mouse alezine lymphoid cell to produce an antibody to the Herpes simplex virus type 1 and type 2 gB glycoprotein.

Doposiať sa protilátky voči virusu Herpes simplex připravovali tak, že virus purifikovaný alebo nepurifikovaný, reap, jeho izolované proteiny boli opakované injikované pokusným zvieratám, najÓaetejaie králíkem, myšiam alebo morčatam. Sérum takto imunizovaných zvlerat, odobrané po viacerých dávkách antigénu alúžllo ako zdroj protilátek, používaných najma pre kvalitativny dokaž antigénu - viruau Herpes simplex - v základném výskume a v imunodiagnostickej praxi (Kalírno K.O.K., Marttila R.O., Granfors K., Viljanen M.K.: Solid-phase radioimmunoassay of human immunoglobulin M and immunoglobulin G antibodies against Herpes simplex virus type 1 capsid, envelope and excreted antigens. Infect. Immun. 15 /1972), 883-889: Leese 3., Hana L., Metis 3.: Reactions of immune sera against the nuclaocapsid. envelope and whole Herpes simplex virus type 1. Acta virol. 20 /1976/, 48-52). Tento postup nazývaný konvenčnou imunizáciou ma niekolko nevýhod. V sére imunizovaných zvlerat sa nachádza heterogénna zmes protilátek, kterých spektrum je v každom organizme iné a neopakovatelné. Organizmus vytvoří okrem protilátek voči žiadanamu antigénu aj protilátky voči nečistotám buňkového povedu nachadzajúcim sa v antigéne. Tieto protilátky je potřebné zo sér odstraňovat vysycévanim. Výrobně šarže konvenčných antisér sa přete dajú tažko Standardizoval! a bývajú v širokém rozmedzi kvality. Pre výrobu kvalitnej šarže aéra třeba připravit čistý imunizačný antigén v dostatečném množstva, čo je najma u vírueu Herpes simplex postup náročný na materiál a technické vybaveníe laboratória. V poslednom čase aá čoraz castejžie používájú na diagnostikovanie herpetických infekci! monoklonálna protilátky, tzv. typovospoločné, ktoré sú schopné reagovat 'a oběma typmi viruau Harpsa simplex.Antibodies to Herpes simplex virus were prepared by repeatedly purifying the virus, purified or unpurified, reap, its isolated proteins, into experimental animals, most preferably rabbits, mice or guinea pigs. Serum of such immunized animals, collected after several doses of antigen, was used as a source of antibodies used mainly for qualitative antigen detection - Herpes simplex virus - in basic research and immunodiagnostic practice (Kalírno KOK, Marttila RO, Granfors K., Viljanen MK: Solid-phase radioimmunoassay of human immunoglobulin M and immunoglobulin G antibodies against Herpes simplex virus type 1 capsid, envelope and excreted antigens (Infect. Immun. 15/1972), 883-889: Leese 3., Hana L., Metis 3 .: Reactions of immune sera against the nuclaocapsid. envelope and whole Herpes simplex virus type 1. Acta virol. 20 (1976), 48-52). This procedure, called conventional immunization, has several disadvantages. The serum of immunized animals contains a heterogeneous mixture of antibodies, the spectrum of which is different and unrepeatable in each organism. In addition to antibodies to the desired antigen, the organism produces antibodies to the cellular impurities present in the antigen. These antibodies need to be removed from the sera by saturation. Production batches of conventional antisera are difficult to standardize! and tend to be in a wide range of quality. For the production of a quality batch of aero, a sufficient amount of pure immunizing antigen must be prepared, which is especially the case with the Herpes simplex virus, which requires the material and technical equipment of the laboratory. Recently, they are increasingly being used to diagnose herpes infections! monoclonal antibodies, so-called species that are able to react with both types of Harpsa simplex virus.

Uvedené nevýhody dotaraz používaných poatupov aa nevyskytnů, ak je k dispozicii hybridómova buňková línia produkujúca typovoapoločnú monoklonálnu protilátku voči glykoproteínu gB vírueu Herpee simplex typ 1 a typ 2, ktorá je uložená v zbierke hybridómov Virologického ústavu SAV, Mlýnská dolina 1, Bratislava pod označením VÚ 144/1-2,The above-mentioned disadvantages of the previously used approaches and the occurrence of a hybridoma cell line producing a type-apolar monoclonal antibody against the glycoprotein gB of the Herpee simplex virus type 1 and type 2, which is stored in the hybridoma collection of the Institute of Virology of the Slovak Academy of Sciences, Mlýnská dolina 1, Bratislava under the designation / 1-2,

Uvedený hybridóm bol zíakaný spósobom známým z odbornej literatúry (Kohler, G., Milstein, C.: Continuous cultures of fused cella secreting antibody of predefined specificity. Nature, 256 /1976/, 495., Gerhard, W.: Fusion of cells in suspension and outgrowth of hybrida in conditioned medium. Monoclonal antibodies: A new dimension in Biological analyses. Kennett R. H. a apol., eda. New York, Plenum Prwss (1980), 370). Hybridné buňky získané po fúzi! myších myelómových Sp2/0 buniek a buniek získaných zo sleziny myši BALB/c imunizovanej zmesou purifikovaných vírusov Herpee simplex typ 1 a typ 2, boli klonované a po otestovaní bol vybraný klon VÚ 159/ 1-9.Said hybridoma was obtained in a manner known from the literature (Kohler, G., Milstein, C .: Continuous cultures of fused cella secreting antibody of predefined specificity. Nature, 256 (1976), 495., Gerhard, W .: Fusion of cells in suspension and outgrowth of hybrida in conditioned medium Monoclonal antibodies: A new dimension in Biological analyzes Kennett RH a apol., eda. New York, Plenum Prwss (1980), 370). Hybrid cells obtained after fusion! mouse myeloma Sp2 / 0 cells and cells obtained from the spleen of BALB / c mice immunized with a mixture of purified Herpee simplex viruses type 1 and type 2 were cloned and, after testing, clone VU 159 / 1-9 was selected.

Výhodou hybridómu je, že produkuje homogénnu protilátku, tzv. monoklonálnu protilátku, ktorá je schopná Specificky reagovat e glykoproteinom gB viruau Herpes simplex typ 1 a typ 2. Hybridóm VÚ 144/1-2 možno kultivovat in vitro v médiach vhodných pre živočišné buňky alebo in vivo v peritoneálnej dutině myši kmeňa BALB/c. Z konzerv zmrazených buniek uchovaných v kvapalnom dusíku, možno začat produkciu protilátky bez SalSej imunizácia zvisrafa antigénom. ‘The advantage of the hybridoma is that it produces a homogeneous antibody, the so-called a monoclonal antibody capable of specifically responding to the Herpes simplex type 1 and type 2 gB glycoprotein. The VU 144 / 1-2 hybridoma can be cultured in vitro in media suitable for animal cells or in vivo in the peritoneal cavity of a BALB / c mouse. From canned frozen cells stored in liquid nitrogen, antibody production can be initiated without SalSej immunization with antigen. ‘

Přiklad:Example:

Za účelem ziskania vačšieho množstva monoklonálnaj protilátky VÚ 144/1-2 kultiváciou hybridómovych buniek in vivo, 5xl06 buniek aa aplikovalo do peritoneálnej dutiny myši. Pra lepšie uchytenie buniek bola myš 15 dni před aplikáciou buniek premedikovaná parafinovým olejom /0,5 ml intraperitoneálne na 1 myč/· Po 10 dňoch rastu hybridómu v peritoneálnej dutině, bola myl zabitá a vyprodukovaná aecltloká tekutina odobrané. Týmto postupem možno priemerne získat asi 7 ml ascitickej tekutiny obsahujúcej 8 mc^/ml protilátky. Ascitická tekutina obaahujúca produkt hybridómu VÚ 144/1-2 vykazovala špaIn order to obtain a larger amount of monoclonal antibody VU 144 / 1-2 by culturing hybridoma cells in vivo, 5x10 6 cells aa were applied to the peritoneal cavity of the mouse. For better cell attachment, the mouse was premedicated with paraffin oil (0.5 ml intraperitoneally per 1 dish) 15 days before the application of the cells. By this procedure, an average of about 7 ml of ascitic fluid containing 8 m 2 / ml of antibody can be obtained. The ascitic fluid surrounding the VU 144 / 1-2 hybridoma product showed spasm

CS 270 537 Bl cifickú vazbu k virueu Herpes simplex typ 1 e typ 2Bv rádioimunoanalytickom teste /RIA/ a v imunoenzymatickej analýze /ELISA/. Metodou rádioimunoprecipitacie a elektroforézy v polyakrylamidovom géli ea zistila vazba monoklonálnej protilátky na glykoprotein gB virusu Herpes simplex typ 1 a typ 2.CS 270 537 Specific binding to Herpes simplex virus type 1 e type 2B in a radioimmunoassay (RIA) and in an immunoenzymatic analysis (ELISA). The binding of the monoclonal antibody to the gB glycoprotein of Herpes simplex virus type 1 and type 2 was determined by radioimmunoprecipitation and polyacrylamide gel electrophoresis ea.

Buňky hybridomu VÚ 144/1-2 rastu in vitro ako polosuspenzná kultúra. Majů guTatý tvar a velkost charakteristickú prs myelómove buňky. Obeahujú fúzované buňkové jadráz sú aneuploidne. Buňky hybridomu VÚ 144/1-2 majú ultraétruktúrny obraz typických myelómovych buniek, kde převážujúcou organelou sú volné a na membránu viazané polyribozómy. Základným kultivačnym médiom je Oulbeccova modífikácia Eagleovho minimálneho esenciálneho média (Dulbecco, R·, Freeman, 6., Virology 8/1959/.396). Toto médium, označované ako OMEM, je pre kultiváciu hybridomu doplněné gentamycinom a inaktivovanym př.ekolostrálnym telacim sérom (1Ó %, Bioveta, Ivanovice na Hané). Hybridóm je kultivovaný pri 37 C v atmosféře 5% CO» . Čeho generačně doba js přibližné 24 h. Produkovaná protilátka je monoklonélny imunoglobulin podtriedy IgGl.VÚ 144 / 1-2 hybridoma cells grown in vitro as a semi-suspension culture. They have the round shape and size characteristic of breast myeloma cells. They fuse the fused cell nuclei from being aneuploid. VÚ 144 / 1-2 hybridoma cells have an ultrastructural image of typical myeloma cells, where the predominant organelle are free and membrane-bound polyribosomes. The basic culture medium is Oulbecco's modification of Eagle's minimal essential medium (Dulbecco, R., Freeman, 6, Virology 8 (1959) .396). This medium, designated OMEM, is supplemented with gentamicin and inactivated precolostral calf serum (10%, Bioveta, Ivanovice na Hané) for hybridoma culture. The hybridoma is cultured at 37 ° C in a 5% CO 2 atmosphere. What the generation time is approximately 24 hours. The antibody produced is a monoclonal immunoglobulin of the IgG1 subclass.

e * ' Aand * 'A

Hybridóm VU 144/1-2 može byť využívaný ako zdroj protilátky voči glykoproteínu gB virusu Herpes simplex typ 1 e typ 2, ktorá sa dá použit na kvalitatlvny dokaž přítomnosti virusu Herpes simplex typ 1 a typ 2 vo vySetrovanom materiále, na kvantitativné stanovenie množstva infikujúceho virusu resp. glykoproteínu gB pri vyhodnocovaní epidemiologickej sltuácie, na purifikaciu glykoproteínu gB z extraktov infikovaných buniek pomocou imunoafinitnej chromatografie a akozdroj protilátky jedinej podtriedy (IgGl) pre přípravu antiser Specifických pre uvedená podtriedu.The VU 144 / 1-2 hybridoma can be used as a source of antibody to the Herpes simplex virus type 1 e type 2 glycoprotein antibody, which can be used to detect the presence of Herpes simplex virus type 1 and type 2 virus in the test material, to quantify the amount of infectious virus resp. glycoprotein gB in the evaluation of epidemiological elution, for the purification of glycoprotein gB from extracts of infected cells by immunoaffinity chromatography and as a source of a single subclass antibody (IgG1) for the preparation of antisera specific for said subclass.

Claims (1)

2 CS 270 537 B1 cifickú vazbu k virusu Herpes simplex typ 1 a typ 2Bv rádioimunoanalytickom taste /RIA/ a v imunoenzymatickej analýze /ELISA/. Metodou rádioimunoprecipitacle a elaktroforézy v polyakrylamidovom géli ea zletilá vazba monoklonálnej protilátky na glykoprotaln gB virusu Herpes simplex typ 1 a typ 2. Buňky hybridómu VÚ 144/1-2 rastu in vitro ako poloeuspenzná kultúra. Majů guZatýtvar a velkost charakteristicko prs myelómove buňky. Obsahujú fúzované buňková jadrázsú aneuploidns. Buňky hybridómu VÚ 144/1-2 májů ultraStruktúrny obraz typických myeló-movych bunisk, kde převážujúcou organslou βύ voZns a na membránu viazaná polyribozómy.Základným kultivačnym médiom je Oulbsccova modífikácia Eagleovho minimálneho esenciál-neho média (Dulbecco, R., Freeraan, 6., Virology 8/1959/.396). Toto médium, označovanéako DMEM, je pre kultiváciu hybridómu doplněné gentamycinom a inaktlvovanym př.ekolostrálnym teZacim sórom (1Ó %, Bioveta, Ivanovice na Hané). Hybridóm je kultivovaný pri 37 C n v atmosféře 5% CO» . 3eho generačně doba je přibližné 24 h. Produkovaná protilátka je monoklonélny imunoglobulin podtriedy IgGl. , , 1 Λ t Hybridóm VU 144/1-2 može byť využívaný ako zdroj protilátky voči glykoproteinu gB virusu Herpes simplex typ 1 a typ 2, ktorá sa dá použit na kvalltativny dokaž přítom-nosti virusu Herpes simplex typ 1 a typ 2 vo vySetrovanom materiále, na kvantitativnéstanovenle množstva infikujúceho virusu resp. glykoproteinu gB pri vyhodnocováni epide-miologickej situácie, na purifikaclu glykoproteinu gB z extraktov infikovaných buniekpomocou imunoafinitnej chromatografie a akozdroj protilátky jedinej podtriedy (IgGl)pre prlpravu antiser Specifických pre uvedenú podtrledu. PREDMET VYNÁLEZU MySi lymfocytárny hybridóm VÚ 144/1-2, produkujúci monoklonólnu protilátku pod-triedy IgGl voči glykoproteinu gB virusu Herpes simplex typ 1 a typ 2.Specific binding to Herpes simplex virus type 1 and type 2B in radioimmunoassay taste (RIA) and in immunoenzymatic analysis (ELISA). The radioimmunoprecipitate and polyacrylamide gel electrophoresis and the adult binding of the monoclonal antibody to the Herpes simplex type 1 and type 2 glycoprotaln gB virus. Growth in vitro hybridoma V144 / 1-2 cells as a semi-suspension culture. The size and the size of the characteristic myeloma cell. They contain fused cell nuclei aneuploidns. VU 144 / 1-2 May Cluster Hybridoma Cell Structure of Typical Myeloma Cells, where the transporting organo-β-voZns and membrane-bound polyribosomes. The basic culture medium is the Oulbscc Modification of Eagle's Minimal Essential Medium (Dulbecco, R., Freeraan, 6. , Virology 8/1959/396). This medium, referred to as DMEM, is supplemented with gentamycin and inactivated precolostal calf sol (1%, Bioveta, Ivanovice na Hane) for hybridoma cultivation. The hybridoma is cultured at 37 ° C in a 5% CO 2 atmosphere. The generation time is about 24 h. The antibody produced is a monoclonal immunoglobulin IgG1 subclass. ,, 1 Λ t Hybridoma VU 144 / 1-2 can be used as a source of Herpes simplex virus 1 glycoprotein antibody type 1 and type 2, which can be used to demonstrate the presence of type 1 and type 2 Herpes simplex virus in the investigated material, quantitative determination of the amount of infecting virus or virus glycoprotein gB in evaluating the epidemiological situation, on the purification of glycoprotein gB from cell infected extracts by immunoaffinity chromatography and a single subclass antibody (IgG1) antibody for the antiserum specific to said subclass. OBJECT OF THE INVENTION MyS1 lymphocyte hybridoma VU 144 / 1-2, producing monoclonal antibody subclass IgG1 to glycoprotein gB Herpes simplex virus type 1 and type 2.
CS888155A 1988-12-09 1988-12-09 V144 / 1-2 lymphocyte hybridoma mice CS270537B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CS888155A CS270537B1 (en) 1988-12-09 1988-12-09 V144 / 1-2 lymphocyte hybridoma mice

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS888155A CS270537B1 (en) 1988-12-09 1988-12-09 V144 / 1-2 lymphocyte hybridoma mice

Publications (2)

Publication Number Publication Date
CS815588A1 CS815588A1 (en) 1989-11-14
CS270537B1 true CS270537B1 (en) 1990-07-12

Family

ID=5431753

Family Applications (1)

Application Number Title Priority Date Filing Date
CS888155A CS270537B1 (en) 1988-12-09 1988-12-09 V144 / 1-2 lymphocyte hybridoma mice

Country Status (1)

Country Link
CS (1) CS270537B1 (en)

Also Published As

Publication number Publication date
CS815588A1 (en) 1989-11-14

Similar Documents

Publication Publication Date Title
Falk et al. Characterization and applications of a monoclonal antibody against infectious salmon anaemia virus
Lee et al. Monoclonal antibodies with specificity for three different serotypes of Marek's disease viruses in chickens.
US4634666A (en) Human-murine hybridoma fusion partner
Koskimies Human lymphoblastoid cell line producing specific antibody against Rh‐antigen D
Brown et al. Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein Barr virus.
Douillard et al. Enzyme-linked immunosorbent assay for screening monoclonal antibody production: use of intact cells as antigen
US4752582A (en) Monoclonal antibodies to human glycophorin A and cell lines for the production thereof
USRE32833E (en) Screening vaccines and immunization process
Vidal et al. A solid-phase enzyme linked immunosorbent assay using monoclonal antibodies, for the detection of African swine fever virus antigens and antibodies
Dittmar et al. Monoclonal antibodies specific for dengue virus type 3
US4818678A (en) Diagnostic system for the detection of cytomegalovirus
CS270537B1 (en) V144 / 1-2 lymphocyte hybridoma mice
Forghani et al. Antisera to human cytomegalovirus produced in hamsters: reactivity in radioimmunoassay and other antibody assay systems
Forghani et al. Serological reactivity of some monoclonal antibodies to varicella-zoster virus
Kao et al. Monoclonal antibodies for the rapid diagnosis of respiratory syncytial virus infection by immunofluorescence
Rouger et al. Study of blood group B antigen with a specific monoclonal antibody (anti-B, b-183)
US4767710A (en) Cell lines for the production of monoclonal antibodies to human glycophorin A
Forghani et al. Production of monoclonal antibodies to human IgM for assay of viral IgM antibodies
Herrmann et al. Preparation and characterization of monoclonal antibodies to enteric adenovirus types 40 and 41
US5556746A (en) Antibodies specific for the group antigen of astroviruses
Dawson et al. Monoclonal antibodies to hepatitis A virus
Ghandour et al. Monoclonal antibodies specific for glial and neuronal antigens in the young rat cerebellum
Thompson et al. Human monoclonal antibodies to human blood group antigens Kidd Jka and Jkb
CS270538B1 (en) Lymphocyte hybridoma VU 159 / 1-9 mice
Hierholzer et al. Application of a solid-phase immunofluorometric assay to the selection of monoclonal antibody specific for the adenovirus group-reactive hexon antigen